Method of enhancing the proliferative phase of a primary T cell response
    1.
    发明授权
    Method of enhancing the proliferative phase of a primary T cell response 有权
    增强原发性T细胞应答增殖期的方法

    公开(公告)号:US09211326B2

    公开(公告)日:2015-12-15

    申请号:US13958558

    申请日:2013-08-03

    摘要: Disclosed is an alkaline extract of shredded pinecones yields a polyphenylpropanoid polysaccharide complex (PPC) that functions as an orally active immune adjuvant. Specifically, the oral PPC boosts the number of antigen-specific memory CD8+ T cells generated in response to a variety of vaccine types (DNA, protein, and dendritic cell) and bias the response towards one that is predominately a T helper 1 type. The oral PPC has potential for use be to enhance the T cell response generated by a variety of prophylactic and therapeutic vaccines designed to target a cellular response.

    摘要翻译: 公开了切碎的松果的碱性提取物产生作为口服活性免疫佐剂的聚苯丙素多糖复合物(PPC)。 具体来说,口服PPC可以增加响应于各种疫苗类型(DNA,蛋白质和树突状细胞)产生的抗原特异性记忆CD8 + T细胞的数量,并将反应偏向主要是T辅助1型的反应。 口服PPC具有用于增强由旨在靶向细胞反应的各种预防和治疗疫苗产生的T细胞应答的潜力。

    METHOD OF ENHANCING THE PROLIFERATIVE PHASE OF A PRIMARY T CELL RESPONSE
    2.
    发明申请
    METHOD OF ENHANCING THE PROLIFERATIVE PHASE OF A PRIMARY T CELL RESPONSE 有权
    增加主要细胞应答的增殖阶段的方法

    公开(公告)号:US20150037373A1

    公开(公告)日:2015-02-05

    申请号:US13958558

    申请日:2013-08-03

    IPC分类号: A61K39/39 A61K39/085

    摘要: Disclosed is an alkaline extract of shredded pinecones yields a polyphenylpropanoid polysaccharide complex (PPC) that functions as an orally active immune adjuvant. Specifically, the oral PPC boosts the number of antigen-specific memory CD8+ T cells generated in response to a variety of vaccine types (DNA, protein, and dendritic cell) and bias the response towards one that is predominately a T helper 1 type. The oral PPC has potential for use be to enhance the T cell response generated by a variety of prophylactic and therapeutic vaccines designed to target a cellular response.

    摘要翻译: 公开了切碎的松果的碱性提取物产生作为口服活性免疫佐剂的聚苯丙素多糖复合物(PPC)。 具体来说,口服PPC可以增加响应于各种疫苗类型(DNA,蛋白质和树突状细胞)产生的抗原特异性记忆CD8 + T细胞的数量,并将反应偏向主要是T辅助1型的反应。 口服PPC具有用于增强由旨在靶向细胞反应的各种预防和治疗疫苗产生的T细胞应答的潜力。